Bempedoic acid and cardiovascular outcomes in statin-intolerant patients
Nissen SE, Lincoff AM, Brennan D, et al.
N Engl J Med. 2023 Mar 4.
Leggi
Patient characteristics, outcomes, and effects of dapagliflozin according to the duration of heart failure: a prespecified analysis of the DELIVER trial
Kondo T, Jering KS, Borleffs CJW, et al.
Circulation. Pub. online 6 Mar 2023.
Leggi
Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
Ridker PM, Bhatt DL, Pradhan AD, et al.
Lancet. 2023;S0140-6736(23)00215-5.
Leggi
Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes – a randomized clinical trial
Pagidipati NJ, Nelson AJ, Kaltenbach LA, et al.
JAMA. 2023;e232854.
Leggi
OZEMPIC: STATO DI CARENZA
6/03/2023
Leggi
Standards of care for the health of transgender and gender diverse people, version 8
Coleman E, Radix AE, Bouman WP, et al.
Int J Transgend Health. 2022;23(Suppl 1):S1-S259.
Leggi
AMD Scientific Talk
Carissimi Soci, come preannunciato in fase di avvio mandato, l’impegno di AMD per lo sviluppo di nuove proposte formative digital è confermato! Stiamo premendo l’acceleratore sull’AMD Digital Network con l’avvio dell’iniziativa AMD Scientific Talk 2022. Che cos'è AMD Scientific Talk 2022? Un programma articolato in una serie di webinar, della durata…
Leggi
Association of long‐term hyperglycaemia and insulin resistance with brain atrophy and cognitive decline: A longitudinal cohort study
Yu JH, Kim REY, Park SY, et al.
Diabetes Obes Metab. 2023;25(4):1091-1100.
Leggi
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS‐1 to ‐5 studies
Lingvay I, Cheng AYY, Levine JÁ, et al.
Diabetes Obes Metab. 2023;25(4):965-974.
Leggi
Distinct mechanisms responsible for the increase in glucose production and ketone formation caused by empagliflozin in T2DM patients
Abdelgani S, Khatab A, Adams J, et al.
Diabetes Care. 2023;dc220885.
Leggi